Mankind Pharma Ltd

Mankind Pharma experienced a notable gain on February 13, 2025, reversing two days of decline and outperforming its sector. The stock reached an intraday high, with mixed trends indicated by moving averages. Despite the one-day gain, Mankind Pharma has seen a decline over the past month, contrasting with the Sensex's modest increase.

Mankind Pharma's stock declined on February 11, 2025, following two days of gains, reaching an intraday low. The company has underperformed its sector and experienced a significant monthly downturn. Its current position relative to various moving averages indicates recent volatility in the broader market context.

Mankind Pharma's stock has declined significantly, losing 3.42% on February 5, 2025, and 4.33% over the past two days. The stock underperformed its sector and has fallen 15.59% in the past month, indicating ongoing volatility and challenges in the market.

Mankind Pharma's stock has declined significantly, losing 3.42% on February 5, 2025, and 4.33% over the past two days. The stock underperformed its sector and has fallen 15.59% in the past month, indicating ongoing volatility and challenges in the market.

Mankind Pharma has faced a significant decline in stock performance, dropping for two consecutive days and accumulating an 8.27% loss. The stock is trading below multiple moving averages and has decreased 16.09% over the past month, underperforming compared to the broader market index.

Mankind Pharma's stock has faced a significant decline today, opening lower and reaching an intraday low. The company has underperformed its sector and experienced a notable drop over the past month, contrasting with the broader market. Its moving averages reflect mixed performance, indicating ongoing challenges.

Mankind Pharma's third-quarter FY24-25 financial results show a mixed performance, with net sales reaching Rs 3,230.00 crore, the highest in five quarters. However, profitability metrics, including Profit Before Tax and Profit After Tax, declined significantly, alongside a substantial rise in interest expenses, indicating financial challenges ahead.

Mankind Pharma experienced a notable stock price increase on January 23, 2025, outperforming its sector. The stock reached an intraday high, indicating a potential trend reversal after previous declines. Despite this uptick, it remains below several key moving averages, reflecting mixed short-term performance amid broader market challenges.

Mankind Pharma experienced a decline on January 21, 2025, following two days of gains, underperforming its sector. The stock's intraday low was Rs 2606, and it remains above its 5-day and 200-day moving averages but below others. The company has seen a notable drop over the past month.

Mankind Pharma has demonstrated notable stock performance, achieving a 3.0% increase on January 20, 2025, and outperforming its sector. The stock reached an intraday high and is currently above several key moving averages, despite a decline over the past month compared to broader market trends.

Mankind Pharma experienced a notable increase in its stock price on January 14, 2025, outperforming its sector. After a series of declines, the stock is now positioned above key moving averages, indicating a potential trend reversal. Its recent performance also surpassed the broader market index, the Sensex.

Mankind Pharma has recently experienced a change in evaluation, reflecting a thorough analysis of its financial metrics and market conditions. The company has demonstrated strong management efficiency, consistent operational results, and a positive technical outlook, alongside a notable increase in institutional holdings.

Mankind Pharma has encountered significant challenges in its stock performance, with a recent decline of 3.95% on January 13, 2025. Over four days, the stock dropped 9.55%, reflecting short-term volatility, although it remains above its 100-day and 200-day moving averages, indicating some long-term stability.

Mankind Pharma has seen a revision in its score amid recent market fluctuations. Despite a decline in stock performance, the company has been added to MarketsMOJO's list, reflecting its resilience in the pharmaceuticals sector. Mankind Pharma's long-term moving averages remain favorable, indicating potential stability ahead.

Mankind Pharma has recently seen a revision in its score from MarketsMOJO, reflecting its strong financial performance and market position. The company reported impressive metrics, including a high return on equity and consistent positive results over six quarters. Mankind Pharma has also been added to MarketsMOJO's list, highlighting its robust growth potential.

Mankind Pharma has recently experienced a revision in its score by MarketsMOJO, reflecting a change in evaluation despite the company's robust financial performance. With strong metrics such as a high return on equity and consistent positive results over six quarters, Mankind Pharma remains a significant player in the pharmaceuticals sector. The stock has also been added to MarketsMOJO's list, highlighting its market position and investor confidence.

Mankind Pharma has recently undergone a revision in its score, reflecting the stock's current market dynamics. Despite a short-term decline, the company remains above key moving averages and has demonstrated notable resilience, outperforming the broader market over the past month. Mankind Pharma has also been added to MarketsMOJO's list, highlighting its strong position in the pharmaceuticals sector.

Mankind Pharma has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's impressive performance. The company achieved a notable gain, reaching a new all-time high and significantly outperforming its sector. This positive trend underscores Mankind Pharma's strong market position and consistent growth.

Mankind Pharma has reached a new 52-week high, reflecting its strong performance in the pharmaceuticals sector. The stock has seen a revision in its score, indicating positive momentum. Additionally, Mankind Pharma has been added to MarketsMOJO's list, underscoring its robust market position and impressive returns over the past year.